PR Newswire/Les Echos/
 
                           
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                
03/06/08 15:06




     The LISI Group presents LISI MEDICAL to the financial community

Today, as part of Analysts Day, the LISI Group presented its Medical Division 
to the financial community. Gilles Kohler, Chairman and Chief Executive, and 
Emmanuel Viellard, the Group's Deputy Chairman, also provided the opportunity 
to meet the management teams of LISI MEDICAL.

This initiative is part of the Group's aim to explain both its diversity and 
the way the different businesses it runs complement each other. Medical 
implants are a new growth area that will contribute to the dynamism and 
international character of LISI over the coming years.

After a presentation of the organization and the competitive advantages of this 
business, the speakers presented the outlook within the LISI Group's overall 
strategy.
LISI effectively opened up a new growth route in 2007 by acquiring three 
specialist medical companies: Hugueny and Seignol, both located in the Lyon 
region, and Jeropa, which is close to San Diego in southern California.
These three companies are manufacturers of fasteners, and orthopaedic 
components and ancillary items (surgical instruments), and are all very close 
to the aerospace world in which LISI has been active for many years. They share 
processes and excellence in quality, manufacturing skills and the management of 
small hitech runs, as well as processing high strength materials such as 
titanium.

Its flagship products are:
         Spinal and orthopaedic implants (Hugueny)
         Dental implants and ancillary products (Jeropa)
         Surgical implants - feet, hands, traumatology, maxillo-facial, dental 
- and manufacture of surgical instruments (Seignol and Intermed Application).

LISI MEDICAL is looking to meet the demand of orthopaedic companies always on 
the lookout for reliable subcontracting solutions, whether they are 
multinationals or innovative specialists without their own production facilities
.
These activities have to meet especially stringent requirements (ISO 13485, EC 
Directive 93/42 modified as 2007/47/EC, FDA Good Manufacturing Practice), with 
strict qualifying processes and flawless quality management.

During 2007, LISI MEDICAL set up a solid organization and now provides 
acknowledged product skills:

        A management team drawn from orthopaedic sector professionals,

        230 staff with experience in the environment and applicable production 
technologies,

        A loyal, repeat customer base that makes up an initial, well-balanced 
portfolio (80% of the division's turnover is from 30 clients),

        4 industrial locations, 2 in France, 1 in the USA and 1 in Morocco, to 
provide a comprehensive service, from raw material to the packaged finished 
product prior to sterilization.

LISI MEDICAL's three main targets in 2008 are:

        To enhance its image and align operations with its positioning as "
Manufacturing Excellence for Life Technologies".

        To consolidate management and its teams and to demonstrate its ability 
to grow at the pace of the market,

        To continue the growth and strengthening of the new division.

                                              1

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                
03/06/08 15:06

LISI MEDICAL will be pursuing innovation around the following six themes:

- Qualification of new products Many prototypes have been prepared together 
with customers at the various locations, whether acetabulum of the pelvis, 
screws for the vertical column, shoulder prosthesis, cervical disks, dental 
implants or matching instrumentation.

- Deployment of new production technologies Alongside classic ongoing progress, 
major advances have been made in high-precision drilling, high-speed, 5-axis 
machining and robotics.

- Industrial organization Having workshops specialize in product families and 
creating if possible independent production cells is being thought through at 
the moment.

- Surface covering - Marking out Based on an original idea, LISI MEDICAL has 
deployed special anodizing units that facilitate creating a wide range of 
colors while complying with the appearance requirements of the medical sector. 
An identical effort has been made to improve the quality and productivity of 
laser marking.
- Decontamination - Packaging
Building a clean room with ISO 7 and ISO 8 areas and ISO 5 laminar flows will 
very soon allow offering packaging suitable for being passed on for 
sterilization. Qualification is under way.
- Approvals management
Management processes and those for industrializing products are currently being 
overhauled, in order to provide clients with complete, systematic, documented 
approvals both of the product and its processes, prior to being put into mass 
production.

At the presentation, Emmanuel Viellard stated, "This new activity is growing in 
a dynamic market, with high growth rates, in certain segments in double digits. 
LISI MEDICAL is on target to post a turnover of about € 25 million in 2008".




Contact
Emmanuel Viellard
Tel: +33 (0)3 84 57 00 77
Email: emmanuel.viellard@lisi-group.com
Website: www.lisi-group.com

The next publications will appear following close of trading on Paris Euronext
2008 Half-year results: July 28, 2008
Financial situation of Q3 2008: October 21, 2008

The LISI share is traded on the Eurolist stock exchange, section B and is part 
of the CAC MID 100 - Next 150
index under ISIN Code FR 0000050353

Reuters Code: GFII.PA
Bloomberg Code: FII FP
 
 
 
 
 
 
 
 
 
 
                                                                                
2



                         
The content and accuracy of news releases published on this site and/or 
distributed by PR Newswire or its partners are the sole responsibility of the 
originating company or organisation. Whilst every effort is made to ensure the 
accuracy of our services, such releases are not actively monitored or reviewed 
by PR Newswire or its partners and under no circumstances shall PR Newswire or 
its partners be liable for any loss or damage resulting from the use of such 
information. All information should be checked prior to publication.